STOCK TITAN

Assembly Biosciences Inc - ASMB STOCK NEWS

Welcome to our dedicated news page for Assembly Biosciences (Ticker: ASMB), a resource for investors and traders seeking the latest updates and insights on Assembly Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Assembly Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Assembly Biosciences's position in the market.

Rhea-AI Summary
Assembly Biosciences, Inc. reported financial results for Q4 2023 and year-end 2023, showcasing progress in antiviral pipeline development. The company entered a partnership with Gilead Sciences, strengthened leadership, and filed a clinical trial application for ABI-5366. Anticipated milestones include interim data from Phase 1a studies by Q3 2024 and Phase 1b studies by end of 2024. Financially, the company's cash position improved significantly, with $130.2 million in cash, cash equivalents, and marketable securities as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
Rhea-AI Summary
Assembly Biosciences, Inc. (ASMB) announced a 1-for-12 reverse stock split of its outstanding shares, reducing the number of shares from approximately 65.8 million to approximately 5.5 million. The split will not affect the number of authorized shares or the par value of the common stock. The split is expected to bring the company into compliance with the minimum bid price requirement for maintaining its listing on The Nasdaq Global Select Market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
stock split
-
Rhea-AI Summary
Assembly Biosciences, a biotechnology company (Nasdaq: ASMB), plans to expand its R&D portfolio across herpesviruses and hepatitis B and D viruses. They anticipate four development candidates to be in the clinic by the end of 2024, with initial clinical data expected by the end of the year from the first-in-human study of long-acting helicase-primase inhibitor targeting recurrent genital herpes (ABI-5366) and Phase 1b study of next-generation core inhibitor for chronic hepatitis B virus (ABI-4334). Assembly Bio recently announced a long-term partnership with Gilead Sciences, Inc. to address serious viral diseases, expanding and building on the progress of their antiviral portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Assembly Biosciences, Inc. (ASMB) Announces Grant of Inducement Awards to Chief Medical Officer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Assembly Biosciences, Inc. (Nasdaq: ASMB) announced new data from its virology portfolio at the American Association for the Study of Liver Diseases (AASLD), highlighting the potential of its preclinical IFNAR agonist program to improve tolerability and the results of vebicorvir in combination with Nrtl and AB-729 in virologically suppressed patients with hepatitis B e antigen negative chronic HBV.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Assembly Biosciences, Inc. (ASMB) has partnered with Gilead Sciences to develop treatments for herpesviruses, HBV, and HDV, with 4 candidates expected in clinical development by the end of 2024. The $100 million upfront payment and investment from Gilead extends cash runway into 2H 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.76%
Tags
earnings
Rhea-AI Summary
ASMB: Assembly Biosciences Announces Dr. Anuj Gaggar as Chief Medical Officer, Bringing Infectious Disease Expertise to Antiviral Programs
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.49%
Tags
none
-
Rhea-AI Summary
Gilead Sciences and Assembly Biosciences have entered into a 12-year partnership to develop antiviral therapies for herpesviruses, hepatitis B virus (HBV), and hepatitis D virus (HDV). Assembly Bio will receive $100 million upfront payment, including an equity investment. Gilead may opt-in for exclusive rights to Assembly Bio's programs and could purchase up to 29.9% of Assembly Bio's voting stock. Assembly Bio may receive up to $330 million per program in potential milestones and royalties. Gilead's EPS is expected to be reduced by $0.05 - $0.07 in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
71.23%
Tags
partnership
-
Rhea-AI Summary
Gilead Sciences and Assembly Biosciences have entered into a 12-year partnership to develop antiviral therapies for herpesviruses, hepatitis B virus (HBV), and hepatitis D virus (HDV). Assembly Bio will receive $100 million upfront payment, including an equity investment. Gilead may opt-in for exclusive rights to Assembly Bio's programs and could purchase up to 29.9% of Assembly Bio's voting stock. Assembly Bio may receive up to $330 million per program in potential milestones and royalties. Gilead's EPS is expected to be reduced by $0.05 - $0.07 in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.62%
Tags
partnership
Rhea-AI Summary
Assembly Biosciences to present preclinical and clinical data at AASLD
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
conferences
Assembly Biosciences Inc

Nasdaq:ASMB

ASMB Rankings

ASMB Stock Data

72.92M
3.63M
32.99%
13.22%
1.1%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
South San Francisco

About ASMB

assembly biosciences, inc. (nasdaq: asmb) is a public clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and novel oral live biotherapeutics for disorders associated with the microbiome. assembly is developing two innovative platform programs: an hbv program advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and a microbiome program developing novel oral live biotherapeutics designed to address diseases associated with the microbiome. assembly’s hbv program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic hbv. the company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current good manufacturing practices and a patent-pending delivery system, gemicel®, which allows for targeted ora